Last reviewed · How we verify

NCT06248866: ESWT

Effect Of Extracorporeal Shock Wave Therapy On Ultrasonography Changes In Patients With Palmar Fibromatosis: A Randomized Controlled Trial

Status unknown NA Last updated 8 February 2024
What this trial tests

NA trial testing Extracorporeal Shock Wave Therapy in Palmar Fibromatosis in 60 participants. Status unknown.

Timeline
10 February 2024
Primary endpoint
10 July 2024
10 July 2024

Quick facts

Lead sponsorCairo University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment60
Start date10 February 2024
Primary completion10 July 2024
Estimated completion10 July 2024

Drugs / interventions tested

Conditions studied

Sponsor

Cairo University

Who can join

Adults 18 to 70, any sex, with Palmar Fibromatosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

this study will be conducted to investigate the effect of extracorporeal shock wave therapy on ultrasonography chnges In patients with palmar fibromatosis

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Extracorporeal Shock Wave Therapy

Trials testing the same drug.

Other Cairo University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06248866.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing